This pharma giant just made a smart strategic acquisition.There are plenty of reasons to buy a leading biopharma business like AbbVie (ABBV -0.99%), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it could now become a prominent psychiatric-drug company.Though the area isn't traditionally in AbbVie's wheelhouse, there's reason to believe that its latest bet will turn out well for investors. Here's why.This new segment could be incredibly valuableOn May ...

Market Trends - Since 1928, there have been 25 bear markets with declines of 20% or more in the S&P 500, while market corrections of 10% or more have occurred 24 times since World War II, with an average decline of 14.1% [1] - The average recovery period after a correction is four months, while bear markets last approximately 1.4 years, followed by bull markets averaging 8.9 years [1] Investment Opportunities - Walmart (WMT) is highlighted as a top stock during market crashes due to its history of outperformance, returning over 23% during the pandemic compared to the S&P 500's 18% [3][4] - Walmart has generated a total return of 462,000% since its IPO, with a $1,000 investment in 1970 now worth $4.6 million [4] - Amazon (AMZN) has shown resilience during market downturns, returning 76% in 2020 compared to the market's 18% gain, and has returned over 188,000% since its 1997 IPO [6][7] - AbbVie (ABBV) has generated 660,000% returns since its spin-off in 2013, outperforming the S&P 500, and returned over 27% during the pandemic [8][9] - AbbVie is expected to maintain sales of $4 billion to $5 billion annually despite losing patent protection on Humira, supported by a strong drug pipeline [9]

Revenue growth during what should be a disastrous patent cliff is encouraging.Wall Street is feeling pretty good about AbbVie's (ABBV -0.35%) performance in 2024 so far.Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen also slapped a $200 price target on the pharma stock, which implies a gain of more than 20% from recent prices.The positive rating is more than a little surprising because AbbVie's lead drug, Humira, lost its market exclusivity in the ...

Core Insights - AbbVie is committed to advancing standards of care in inflammatory bowel diseases (IBD) by presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, including three oral presentations focused on Crohn's disease and ulcerative colitis [1][2][30] Group 1: Research and Presentations - The SEQUENCE trial will present data comparing the efficacy of risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease, including an economic analysis and inflammation biomarkers [1][3] - Additional studies will evaluate the efficacy and safety of risankizumab in both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study for ulcerative colitis [1][3] - Notable presentations include the achievement of clinical remission and reduction in inflammatory biomarkers in patients with moderate-to-severe Crohn's disease from the Phase 3b SEQUENCE Trial [5] Group 2: Company Strategy and Commitment - AbbVie aims to enhance the understanding of IBD and improve patient outcomes by building a diverse portfolio of marketed and investigational products [2][30] - The company emphasizes the importance of addressing both acute needs and long-term care goals for IBD patients, showcasing its leadership in gastroenterology [2][30] - AbbVie is focused on driving discoveries and advancing science to elevate the standards of care for individuals living with IBD [2][30]

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment. Additionally, these businesses range from consumer staple giants to aerospace titans and healthcare juggernauts. They provide a fundamental combination of operational efficiency, strategic vision, and market supremacy.The first demonstrates its durability and innovative capability in the healthcare industry with a balanced ex ...

What could be better than well-established retirement stocks to buy that you can trust? How about adding to that confidence level with the backing of Wall Street analysts.To be sure, analysts by themselves don’t dictate nor perfectly predict the success or failure of publicly traded enterprises. If it were that simple, everybody would simply follow their recommendations to a “T.” However, these experts assess companies for a living and their livelihood in many ways depend on their reputation.So, it’s a good ...

Core Insights - AbbVie is focusing on its growth platform, which constitutes 80% of its business and is expected to grow in the mid-teens, despite the erosion of HUMIRA sales [2][3][5] - The company anticipates robust growth in the coming years, projecting above industry average growth, with a high single-digit compound growth rate expected throughout this decade [3][12][13] Growth Platform Performance - The growth platform is projected to deliver $5.6 billion in growth this year, with mid-teens growth from the ex-HUMIRA portfolio [3][5] - SKYRIZI and RINVOQ are performing exceptionally well, with significant market share capture and continued momentum in inflammatory bowel disease (IBD) indications [4][6][9] HUMIRA Erosion Management - HUMIRA sales declined by approximately $6.5 billion last year and are expected to decline to about $4.5 billion this year, but AbbVie is managing this erosion effectively [5][12] - The company has successfully returned to growth one year after the U.S. HUMIRA loss of exclusivity (LOE), a feat not achieved by others in the industry [5][12] Oncology Pipeline - AbbVie has exciting oncology programs, including a BCMA CD3 bispecific in myeloma and an ADC using the Topo-1 warhead, with a strong start for ELAHERE [6][19] - The company is entering Phase III trials for ABBV-400 in colon cancer, showing promising response rates in a refractory patient population [19][20] Future Indications and Growth - SKYRIZI is expected to receive UC approval mid-year, which will further enhance its growth trajectory [8][9] - RINVOQ has a wave of new indications anticipated between 2026 and 2028, which could add several billion dollars in peak revenue [8][9] Part D Benefit Changes - The redesign of the Part D benefit is expected to impact growth, particularly in immunology and oncology, but AbbVie has already factored this into its guidance [11][12] - Despite the anticipated impact, the company expects to maintain robust growth above industry averages [12][13] Aesthetics Business Recovery - The U.S. toxin market has returned to growth, with mid-single-digit growth observed in the first quarter, and AbbVie projects high single-digit growth for its aesthetics business this year [44][45] - The company has maintained its market share for Botox despite competition from DAXXIFY, indicating resilience in its product offerings [44][45] Business Development Focus - AbbVie is prioritizing assets that can drive growth in the next decade, particularly in immunology and oncology, while also investing in early-stage opportunities [50][51] - The company is not constrained by its balance sheet but is strategically focused on deepening its core therapeutic areas [52][54]

AbbVie, Inc. (NYSE:ABBV) Conference Call Summary Company Overview - **Company**: AbbVie, Inc. - **Date**: May 15, 2024 - **Participants**: - Robert Michael - CEO - Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics - Jeffrey Stewart - COO - **Industry**: Healthcare, specifically focusing on pharmaceuticals and biotechnology Key Points 1. Growth Platform Performance - The growth platform constitutes 80% of AbbVie's business and is experiencing mid-teens growth, contributing $5.6 billion in growth this year alone [2][3] - The company anticipates robust growth next year, projecting above industry average growth, ultimately aiming for high single-digit compound growth throughout the decade [3][5] 2. HUMIRA Erosion and Management - HUMIRA's revenue declined by approximately $6.5 billion last year and is expected to decline to about $4.5 billion this year [5] - Despite HUMIRA's erosion, AbbVie is returning to growth one year post the U.S. HUMIRA loss of exclusivity (LOE), a feat not achieved by others in the industry [5][13] 3. SKYRIZI and RINVOQ Outlook - SKYRIZI and RINVOQ are performing exceptionally well, with significant market share capture and continued momentum in inflammatory bowel disease (IBD) indications [4][6] - SKYRIZI is expected to receive UC approval mid-year, which will further enhance its growth trajectory [8] - RINVOQ is projected to expand into new indications by 2026-2028, potentially adding several billion dollars in peak revenue [9] 4. Oncology Pipeline Developments - AbbVie is focusing on its ADC (antibody-drug conjugate) pipeline, with promising programs in oncology, including ELAHERE and ABBV-400 [6][19] - The company is entering Phase III trials for ABBV-400 in colon cancer, showing greater depth of response compared to previous treatments [19][20] 5. Part D Benefit Changes - The redesign of the Part D benefit is expected to impact growth, particularly in immunology and oncology, but AbbVie has already factored this into their guidance [11][12] - The company anticipates several points of growth despite the changes, maintaining a robust growth outlook [12][13] 6. Aesthetics Business Recovery - The U.S. toxin market has returned to growth, with mid-single-digit growth observed in the first quarter [44] - AbbVie projects high single-digit growth for its aesthetics business, aiming for over $9 billion by 2029 [45][48] 7. Business Development Strategy - AbbVie is focusing on smaller-sized opportunities that can drive long-term growth, particularly in immunology and oncology [50][51] - The company is committed to maintaining a net leverage of 2x within 2-3 years while pursuing growth opportunities [52] 8. Competitive Landscape in Neuroscience - AbbVie is optimistic about its position in the neuroscience market, particularly with the development of tavapadon for Parkinson's disease [30][32] - The company believes its product profile offers advantages over competitors, enhancing its market share potential [36] 9. Market Dynamics and Share Performance - AbbVie has maintained its market share in the aesthetics segment despite competition from new entrants like DAXXIFY [44] - The company is seeing strong performance in its Juvederm family, contributing to overall share growth [45] 10. Future Growth Drivers - AbbVie is exploring innovative products, including short-acting toxins and regenerative fillers, to drive growth in the aesthetics market [48] - The company is also looking to expand its ADC capabilities and enhance its oncology portfolio through strategic investments [50][51] Conclusion AbbVie is navigating a transitional phase with the erosion of HUMIRA while focusing on its growth platforms, particularly SKYRIZI and RINVOQ. The company is optimistic about its oncology pipeline and aesthetics business recovery, with a strategic focus on smaller, high-potential opportunities for long-term growth.

Core Insights - The article discusses the evolving workplace dynamics, particularly focusing on how companies are adapting to the needs of a diverse workforce, including Gen Z, by offering wellness benefits and emphasizing diversity and inclusion [2][3]. - The 2024 "Fortune 100 Best Companies to Work For" list highlights companies that create positive work experiences for all employees, not just management, and emphasizes the importance of employee feedback in ranking [2][3]. - A total of 44 out of 100 eligible companies are private entities, with 56 publicly owned companies being viable candidates for investment, of which 44 pay dividends [2][3]. Company Performance and Investment Opportunities - Two recommended dividend stocks from the Fortune 100 Best Companies to Work For list are DHL Group and HP Inc, both showing annual dividends exceeding their share prices, indicating potential investment opportunities [3][4]. - Analysts project net gains ranging from 10.62% to 24.03% for ten selected companies from the Fortune 100 Best Companies to Work For list [4]. - The average net gain for a $10,000 investment across ten high-yielding stocks is estimated at 15.22%, with varying levels of risk and volatility compared to the market [9][10]. Dividend Stocks Analysis - The top ten dividend stocks by yield from the Fortune 100 Best Companies to Work For include companies from various sectors, with notable mentions being Comcast Corp, First American Financial, and Nucor Corp, each projected to have significant upside potential [14][15]. - The article provides a detailed analysis of projected net gains for specific stocks, with Comcast Corp expected to yield a net gain of $240.34 based on analyst estimates [6][7]. - The analysis categorizes stocks as "dogs" based on their reliable dividends and price performance, highlighting the importance of yield in investment decisions [10][17].

Group 1 - AbbVie Inc. has signed a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric conditions, with an upfront payment of $65 million and potential total payments of up to $1.95 billion [1][2] - The partnership aims to leverage AbbVie's expertise in psychiatry and Gilgamesh's research platform to discover novel neuroplastogens, which may address challenges associated with classic psychedelic compounds [2] - AbbVie has seen a 4.1% increase in shares year-to-date, while the industry has risen by 13.4%, indicating a need for strategic partnerships to drive long-term growth [3] Group 2 - AbbVie's neuroscience portfolio includes Vraylar, which generated $694 million in sales in Q1 2024, reflecting a 23.6% year-over-year increase [3] - AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, which will enhance its neuroscience pipeline with new candidates for various psychiatric and neurological disorders [4][5] - The acquisition is expected to close in mid-2024, pending shareholder and regulatory approval [5]